Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression
By: Jiamin Du, Meijia Qian, Tao Yuan, Bo Zhang, Xueqin Chen, Ning An, Qiaojun He, Bo Yang, Song Ye and Hong Zhu
Authors
Jiamin Du
Zhejiang Province Key Laboratory of Anticancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
Meijia Qian
Zhejiang Province Key Laboratory of Anticancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
Tao Yuan
Zhejiang Province Key Laboratory of Anticancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
Bo Zhang
Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
Xueqin Chen
Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People´s Hospital, Zhejiang University School of Medicine, Hangzhou, China
Ning An
Department of Pharmacy, Ningbo Medical Center Lihuili Hospital, Ningbo, China
Qiaojun He
Zhejiang Province Key Laboratory of Anticancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
Bo Yang
Zhejiang Province Key Laboratory of Anticancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
Song Ye
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Second Affiliated Hospital, School of Medicine Zhejiang University, Hangzhou, China
Hong Zhu
Zhejiang Province Key Laboratory of Anticancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
The Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China
Language: English
Page range: 427 - 436
Accepted on: Jan 19, 2022
Published on: Apr 13, 2022
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2022 Jiamin Du, Meijia Qian, Tao Yuan, Bo Zhang, Xueqin Chen, Ning An, Qiaojun He, Bo Yang, Song Ye, Hong Zhu, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.